ONT-10

BIOLOGICAL2 trials

Sponsors

Cascadian Therapeutics Inc.

Conditions

Solid Tumors

Phase 1

Phase 1 Study of ONT-10 in Patients With Solid Tumors

CompletedNCT01556789

Cascadian Therapeutics Inc.Solid Tumors

Start: 2013-03-31End: 2015-09-30Updated: 2018-05-17

Phase 1b Maintenance Therapy Study of ONT-10 in Patients With Solid Tumors

CompletedNCT01978964

Cascadian Therapeutics Inc.Solid Tumors

Start: 2012-11-30End: 2016-03-31Target: 90Updated: 2018-05-17

Related Papers

Tolerability, humoral immune response, and disease control in phase 1 patients receiving ONT-10, a MUC1 liposomal vaccine.

Journal of Clinical Oncology2014-05-207 citations